



OPEN ACCESS

EDITED AND REVIEWED BY Ira Ida Skvortsova, Innsbruck Medical University, Austria

*CORRESPONDENCE

Changhua Zhang,

Yulong He,

Axel Behrens

□ axel.behrens@crick.ac.uk

[†]These authors share first authorship

RECEIVED 24 July 2025 ACCEPTED 08 August 2025 PUBLISHED 28 August 2025

Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y and Zhang C (2025) Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway.

Front Cell Dev Biol 13:1672461 doi: 10.3389/fcell.2025.1672461

© 2025 Li, Wang, Lan, Wu, Evans, Ruiz, Yan, Zhou, Oliveira, Reis, Hu, Chen, Behrens, He and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

Huafu Li^{1,2,3,4†}, Chunming Wang^{1,4†}, Linxiang Lan^{2,3†}, Wenhui Wu^{1†}, Ian Evans^{2,3}, E. Josue Ruiz^{2,3}, Leping Yan⁵, Zhijun Zhou⁶, Joaquim M. Oliveira^{7,8}, Rui L. Reis^{7,8}, Zhenran Hu⁶, Wei Chen¹, Axel Behrens^{2,3}*, Yulong He^{1,4}* and Changhua Zhang¹*

¹Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China, ²Adult Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom, ³The Institute of Cancer Research, London, United Kingdom, ⁴Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁵Center of Scientific Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China, ⁶Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, 73B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, Guimarães, Portugal, ⁸ICVS/3B's – PT Government Associate Laboratory, Guimarães, Portugal

KEYWORDS

gastric cancer, L-OHP resistance, homologous recombination, PARP1 inhibitors, organoid

A Corrigendum on

PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

by Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y and Zhang C (2021). Front. Cell Dev. Biol. 9:719192. doi: 10.3389/fcell.2021.719192

There was a mistake in Figures 2, 4 as published. The wrong images were erroneously used for Figures 2G, 4A. The corrected Figures 2, 4 appear below.

Li et al. 10.3389/fcell.2025.1672461




FIGURE 2
PARP1 is upregulated in oxaliplatin resistance gastric cancer. (G) Representative images of PARP1 levels stained by immunofluorescence in organoid and tumors. The scale bar represents 20 µm for tumour images, 200 µm for organoid images.




FIGURE 4
PARP1 inhibition by Olaparib sensitizes gastric cancer to Oxaliplatin.
(A–C) rGC1 organoids were treated with Olaparib + Oxaliplatin,
Oxaliplatin, and Olaparib, respectively, before imaging (A), number of organoids (B), and size of organoids (C). The scale represents 500 µm.

The original version of this article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.